

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Content Development Manager:** Pien van Spijker**Journal Manager:** Bharathi Sims**Publisher:** Fernanda Ogochi**Editorial Enquiries:***Drug Discovery Today*

Elsevier

125 London Wall, London, EC2Y 5AS, UK

Tel: +44 (0) 20 8439 5525

Fax: +44 (0) 1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Integrated Profiling, USA***David Cavalla** *Numedicus Ltd., UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *ALN Associates, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Merck, USA***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, China***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Meliior Discovery, USA***Lorenz Mayr** *AstraZeneca, UK***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *AstraZeneca, USA***Mark Murcko** *Disruptive Biomedical, LLC, USA***Fajun Nan** *Shanghai Institute of Materia Medica, China***Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Clinical Semantics Group Consulting, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Microbiotix, Inc., USA***Manuel Peitsch** *Swiss Institute of Bioinformatics, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA***Janice Reichert** *Reichert Biotechnology Consulting LLC, MA, USA***John Reidhaar-Olson** *Albert Einstein College of Medicine, New York, USA***Mike Romanos** *Crescendo Biologics, Cambridge, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *EFS Strategy and Business Consulting, UK***Jonathan Sheldon** *Translational Medicine, Oracle, UK***Michael Snyder** *Stanford University, USA***Susie Stephens** *Johnson & Johnson, USA***Robert Strausberg** *Ludwig Institute for Cancer Research, New York, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Janssen Pharmaceutica, Belgium***Limsoon Wong** *National University of Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

- 873 Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases**
Asahi Tomitaka, Ajeet Kaushik, Bhavesh D. Kevadiya, Insiya Mukadam, Howard E. Gendelman, Kamel Khalili, Gang Liu and Madhavan Nair
- 883 A unified mapping framework of multifaceted pharmacodynamic responses to hypertension interventions**
Qian Wang, Jingwen Gan, Kun Wei, Scott A. Berceci, Claudia Gragnoli and Rongling Wu
- 890 Adverse drug reactions on sexual functioning: a systematic overview**
Rineke Gordijn, Martina Teichert, Melianthe P.J. Nicolai, Henk W. Elzevier and Henk-Jan Guchelaar
- 898 Fullerene-based delivery systems**
Houman Kazemzadeh and Masoud Mozafari
- 906 Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor**
Sergio C. Chai, Wenwei Lin, Yongtao Li and Taosheng Chen
- 916 Phosphinic acids: current status and potential for drug discovery**
Moaz M. Abdou, Paul M. O'Neill, Eric Amigues and Magdalini Matziari

FORTHCOMING ARTICLES:**Müller cells as a target for retinal therapy.***By Joke Devoldere, Karen Peynshaert, Stefaan C. De Smedt, Katrien Remaut.***Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.***By Astrid Subrizi, Eva M. del Amo, Viktor Korzhakov-Vlakh, Tatiana Tennikova, Marika Ruponen and Arto Urtti.***Modified cells as potential ocular drug delivery systems.***By Tatiana Tennikova1 and Arto Urtti***Connexin43 hemichannels: a potential drug target for the treatment of diabetic retinopathy.***By Odunayo O. Mugisha, Colin R. Green, Jie Zhang, Monica L. Acosta and Ilva D. Rupenthal.*